Managing osteoporosis and bone health in Duchenne muscular dystrophy occurs in a high-risk environment for fractures due to disease-related loss of muscle and movement, adverse effects of ...

University of Manchester scientists have mapped the mutations in the tiny protein chains that cause a subtype of muscular ...

Dr. Jerry Mendell, who co-invented the gene therapy, said "treating boys with Duchenne muscular dystrophy after seeing their natural history and decline over and over and over for the past 50 ...

The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...

University of Manchester scientists have mapped the mutations in the tiny protein chains that cause a subtype of muscular ...

Charlie has Duchenne muscular dystrophy, a degenerative genetic disease that, until recently, has guaranteed death by early adulthood from cardiac or respiratory failure.

After decades of research, gene therapy has been approved for Duchenne Muscular Dystrophy, a degenerative muscle disease diagnosed each year in about 1 in 3,500 newborns, almost all boys.

Duchenne Muscular Dystrophy may no longer be a death sentence. Oct. 17, 2012— -- Although he made it to 29 years old with Duchenne muscular dystrophy, Jason Williams was not expected to ...

Duchenne muscular dystrophy is rare Duchenne is a rare, progressive disorder in which muscle cells are in a constant state of destruction. Need a break? Play the USA TODAY Daily Crossword Puzzle.

Deflazacort, a newly FDA-approved drug for Duchenne muscular dystrophy, has an $89,000-a-year price tag. It has been put on hold because of an uproar over drug prices.

The Food and Drug Administration Monday approved the first drug to treat Duchenne muscular dystrophy, a rare and lethal muscle weakening disorder that affects about 15,000 Americans.